Eris Lifesciences (BOM:540596) Total Liabilities : ₹38,268 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Total Liabilities?

Eris Lifesciences's Total Liabilities for the quarter that ended in Mar. 2024 was ₹38,268 Mil.

Eris Lifesciences's quarterly Total Liabilities declined from Sep. 2023 (₹14,476.15 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹38,268.06 Mil).

Eris Lifesciences's annual Total Liabilities increased from Mar. 2022 (₹3,639.36 Mil) to Mar. 2023 (₹14,466.51 Mil) and increased from Mar. 2023 (₹14,466.51 Mil) to Mar. 2024 (₹38,268.06 Mil).

Eris Lifesciences Total Liabilities Historical Data

The historical data trend for Eris Lifesciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Total Liabilities Chart

Eris Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

2,559.71

2,583.57

3,639.36

14,466.51

38,268.06

Eris Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															14,466.51	-	14,476.15	-	38,268.06

Eris Lifesciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Eris Lifesciences's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	25320.77	+	(6915.26	+	6032.03
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	38,268

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	70488.37	-	32220.31
	=	38,268

Eris Lifesciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	25320.77	+	(6915.26	+	6032.03
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	38,268

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	70488.37	-	32220.31
	=	38,268

Eris Lifesciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eris Lifesciences (BOM:540596) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Total Liabilities

Traded in Other Exchanges

ERIS:India

Address

Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054

Website

https://www.eris.co.in

Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines